Compare AbbVie Inc (ABBV) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Raytheon Technologies Corp — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Raytheon Technologies Corp trades at $223.86 (market cap $302.06B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | RTX | |
|---|---|---|
Market Cap | $438.19B | $302.06B |
Sector | Health | Industrials |
52-Week High | $263.58 | $224.12 |
52-Week Low | $197.38 | $151.75 |
Enterprise Value | $502.45B | $332.61B |
Dividend Yield | 2.79% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
RTX trades at $223.86, up 0.37% today, with a bullish technical signal and strong analyst consensus of 17 buys and a $233.14 price target. Recent earnings beats and a $515 million Navy radar contract (PRNewsWire, June 3, 2026) highlight operational momentum. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.28%, though a P/E of 39.46 suggests premium valuation.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation and geopolitical dependencies. Cash flow trends show strengthening operations, supporting dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
